All In Biotech

Drug Trial Radar · NCT07456891

Remibrutinib Open Label Roll-over Post-trial Access Protocol

An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Remibrutinib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Remibrutinib.

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

650

Planned (sponsor's estimate)

Start

Apr 16, 2026

Primary completion

Jan 30, 2033

Study completion Jan 30, 2033

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a Novartis-sponsored study, who are benefiting from treatment with remibrutinib, and are unable to access remibrutinib treatment outside of a clinical study.

Conditions

  • Indication of the Parent Protocol

Interventions

  • RemibrutinibDrug

    Remibrutinib film coated tablets in the respective dose strength of the parent study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with the occurrence of AEs or SAEsTime frame: throughout the study, approximately 7 years

Locations

46 sites in 9 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Sofia, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sofia, Bulgaria · Recruiting

  • Novartis Investigative Site

    Varna, Bulgaria · Recruiting

  • Novartis Investigative Site

    Fredericton, New Brunswick, Canada · Recruiting

  • Novartis Investigative Site

    Hamilton, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    London, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Québec, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Verdun, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia · Recruiting

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia · Recruiting

  • Novartis Investigative Site

    Brno, Czechia · Recruiting

  • Novartis Investigative Site

    Plzen Bolevec, Czechia · Recruiting

  • Novartis Investigative Site

    Prague, Czechia · Recruiting

  • Novartis Investigative Site

    Prague, Czechia · Recruiting

  • Novartis Investigative Site

    Bordeaux, France · Recruiting

  • Novartis Investigative Site

    Brest, France · Recruiting

  • Novartis Investigative Site

    Montpellier, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Pierre-Bénite, France · Recruiting

  • Novartis Investigative Site

    Rouen, France · Recruiting

  • Novartis Investigative Site

    Saint-Mandé, France · Recruiting

  • Novartis Investigative Site

    Gdansk, Poland · Recruiting

  • Novartis Investigative Site

    Gdansk, Poland · Recruiting

  • Novartis Investigative Site

    Poznan, Poland · Recruiting

  • Novartis Investigative Site

    Krosno, Krosno, Poland · Recruiting

  • Novartis Investigative Site

    Poznan, Poland, Poland · Recruiting

  • Novartis Investigative Site

    Gwangju, South Korea · Recruiting

  • Novartis Investigative Site

    Incheon, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Daegu, Dalseo gu, South Korea · Recruiting

  • Novartis Investigative Site

    Ansan, Gyeonggi-do, South Korea · Recruiting

  • Novartis Investigative Site

    Hwaseong-si, Gyeonggi-do, South Korea · Recruiting

  • Novartis Investigative Site

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Novartis Investigative Site

    Dongjak Gu, Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Alicante, Spain · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Córdoba, Spain · Recruiting

  • Novartis Investigative Site

    Las Palmas GC, Spain · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.